| Literature DB >> 32727501 |
Serife Ayaz-Guner1, Nicola Alessio2, Mustafa B Acar3,4, Domenico Aprile2, Servet Özcan3,4, Giovanni Di Bernardo2, Gianfranco Peluso5, Umberto Galderisi6,7,8.
Abstract
BACKGROUND: The term mesenchymal stromal cells (MSCs) designates an assorted cell population comprised of stem cells, progenitor cells, fibroblasts, and stromal cells. MSCs contribute to the homeostatic maintenance of many organs through paracrine and long-distance signaling. Tissue environment, in both physiological and pathological conditions, may affect the intercellular communication of MSCs.Entities:
Keywords: Mesenchymal stromal cells; Obesity; Secretome
Year: 2020 PMID: 32727501 PMCID: PMC7388533 DOI: 10.1186/s12964-020-00614-w
Source DB: PubMed Journal: Cell Commun Signal ISSN: 1478-811X Impact factor: 5.712
Number of proteins per secretome
| HFD | ND | |
|---|---|---|
| 444 | 487 | |
| 510 | 573 | |
| 381 | 257 |
.
| Common GO among vWAT sWAT BM | GO vWAT specific | GO sWAT specific | GO BM specific | |
|---|---|---|---|---|
Fig. 1Main GO ontologies identified in secretome samples. The pictures depict some common ontologies identified by PANTHER analysis in the secretomes of vWAT-MSCs, sWAT-MSCs, and BM-MSCs. In orange are factors classified according GO Biological activity and GO Pathway, while in blue are classified according GO Cellular component, GO Protein class and GO molecular function
.
| Common GO among vWAT sWAT BM | GO vWAT specific | GO sWAT specific | GO BM specific | |
|---|---|---|---|---|
.
Fig. 2Cross-presentation of soluble exogenous antigens (endosomes) pathway. The pathway consists of three main networks: antigen processing—cross-presentation; antigen presentation—folding, assembly, and peptide loading of class I MHC; and antigen processing—ubiquitination and proteasome degradation. During the presentation process, antigen proteins are degraded into peptides by proteases in the proteasome. Peptides are then delivered to the endoplasmic reticulum (ER) through heat shock proteins and the transporter associated with antigen processing (TAP), which transport peptides from cytosol into the ER lumen. Several ER chaperones (calnexin, tapasin, calreticulin, etc.) contribute to MHC-I assembly. Peptides are loaded into the MHC-I peptide binding groove; this complex exits the ER and is transported to Golgi and then to the cell surface by exocytic vesicles. Naïve T cells (CD8+) are activated by interacting with peptide-MHC-I complexes. Additional file 4 reports the proteins of vWAT-MSC, sWAT-MSC, and BM-MSC secretomes that belong to the above-indicated networks
Fig. 3Platelet degranulation pathway. This pathway consists of several networks: ABCC4 accumulation of dense granule contents; exocytosis of platelet dense granule content; surface deployment of platelet dense granule membrane components; exocytosis of platelet alpha granule contents; surface deployment of platelet alpha granule membrane components; release of platelet cytosolic components; release of platelet secretory granule components; and exocytosis of proactivator polypeptide. Platelets are activated following the interaction between ligands, such as ADP and TXA2 (Tromboxane A2), and their cognate receptors on the platelet cell surface. After activation, platelets release the contents of three distinct types of preformed intracellular vesicles. Dense granules (δ granules) contain platelet agonists, and lysosomes contain glycosidases and acid proteases. The α granules release adhesive proteins, prothrombotic factors, and pro-inflammatory factors. Additional file 4 reports the proteins of vWAT-MSC, sWAT-MSC, and BM-MSC secretomes that belong to these networks
Fig. 4Regulation of insulin-like growth factor (IGF) transport and uptake by insulin-like growth factor binding proteins (IGFBPs) pathway. The pathway consists of several networks: IGFBP1 binds with IGF, forming IGF:IGFBP1; IGFBP2 binds with IGF, forming IGF:IGFBP2; IGFBP4 binds with IGF, forming IGF:IGFBP4; IGFBP6 binds with IGF, forming IGF:IGFBP6; PAAP-A proteolyzes IGF:IGFBP4; FAM20C phosphorylates FAM20C substrates. IGF-I binds to its receptor (IGF-IR), which leads to IRS/PI3K phosphorylation and subsequent downstream activation of AKT. Alternatively, IGF-I can activate Shc/Grb-2/Sos phosphorylation and complex formation. This event promotes the activation of the Ras/Raf/MEK/MAPK cascade. IGF-I binds to the hybrid IGF-IR/IR receptor, activating PI3K and MAPK pathways. The IGF-II/IGF-IIR complex can activate an alternative pathway that is associated with the G protein and phospholipase C (PLC). The result of the PLC activity is the production of diacylglycerol (DAG) and inositol triphosphate (IP3), which in turn can activate protein kinase C (PKC) and the RAF/MEK/ERK pathway. IGF-I also binds with IGF-IIR, and IGF-II also binds with IGF-IR. It not well-known which pathways are activated following these interactions. IGFBP proteins bind with either IGF-I or IGF-II and modulate their activities
.
Fig. 5Venn diagram analysis. Top left: Venn diagram showing common and specific proteins among secretomes obtained from vWAT-MSCs, sWAT-MSCs, and BM-MSCs isolated from samples taken from normal mice (ND). Top right: Venn diagram showing common and specific proteins among secretomes obtained from vWAT-MSCs, sWAT-MSCs, and BM-MSCs isolated from samples taken from obese mice (HFD). Bottom: Venn diagram comparison of vWAT-MSCs from normal mice with vWAT-MSCs from obese mice. The same procedure was applied for sWAT-MSCs and BM-MSCs. Numbers indicate common and specific proteins for every comparison
Proteins specifically expressed in the indicated secretomes
| Ang | Gmfb | ||
| Angptl4 | Manf | ||
| Fstl3 | |||
| Pgf | |||
| Ptgr1 | Cd81 | Ccl9 | |
| Csfr1 | Ifi30 | ||
| Catalase | Glc | ||
| Gsr | Prdx5 | ||
| Prdx6 | |||
| Blvra | Aldh1a3 | ||
| Crat | Aldh1a2 | ||
| Nampt | Me1 | ||
| Sorcin | |||
| Cemip | |||
| Itih3 | |||
| Vcan | |||
| Hdgf | Igf2 | Fstl3 | |
| Ostf1 | |||
| Tgm2 | |||
| Cfh | |||
| Fdps | Lipa | ||
| Pla1a | |||
| Hyou1 | |||
| Mt1 |